title: Differences in repair of DNA cross-links between lymphocytes and epithelial tumor cells from colon cancer patients measured in vitro with the comet assay.
abstract: OBJECTIVE
  The more common approach to comet assay studies with cancer patients involves indirect measurement of the effect of antineoplastic drug or radiation regimen by assessing DNA damage in surrogate cells, such as peripheral blood lymphocytes of cancer patients, to predict how tumor cells may be affected. The aim of the present study was to compare the capability of different cells isolated from a series of 23 colon cancer patients to repair the damage induced by a cancer drug.
  
  
  METHODS
  We adapted the in vitro comet repair assay for nucleotide excision repair to measure the ability of lymphocytes and normal and tumor epithelial colon cells to remove DNA cross-links induced by oxaliplatin. The excision repair rate was measured quantitatively by the tail parameters: tail DNA, tail length, extent tail moment, and olive tail moment.
  
  
  RESULTS
  Kruskal-Wallis analysis revealed significant differences in recognition and excision activity between different cell types (P < 0.001) for all the comet parameters studied. Hence, colon cells showed higher recognition and excision activity than lymphocytes and tumor cells displayed the highest repair capability. We found no significant correlation between the repair activity of tumor colon cells and lymphocytes in any of the comet parameters considered.
  
  
  CONCLUSIONS
  Our data support the view that lymphocyte repair activity is not predictive of the repair ability of the tumor and that lymphocytes cannot act as surrogate cells.
authors.affiliation: Department of Medical Oncology, Puerta de Hierro-Majadahonda University Hospital, Madrid, Spain.
authors.forename: Mercedes
authors.initials: M
authors.lastname: Herrera
authors.forename: Gemma
authors.initials: G
authors.lastname: Dominguez
authors.forename: Jose M
authors.initials: JM
authors.lastname: Garcia
authors.forename: Cristina
authors.initials: C
authors.lastname: Peña
authors.forename: Carmen
authors.initials: C
authors.lastname: Jimenez
authors.forename: Javier
authors.initials: J
authors.lastname: Silva
authors.forename: Vanesa
authors.initials: V
authors.lastname: Garcia
authors.forename: Irene
authors.initials: I
authors.lastname: Gomez
authors.forename: Raquel
authors.initials: R
authors.lastname: Diaz
authors.forename: Paloma
authors.initials: P
authors.lastname: Martin
authors.forename: Felix
authors.initials: F
authors.lastname: Bonilla
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D020552:Comet Assay; D004249:DNA Damage; D004260:DNA Repair; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D018709:Statistics, Nonparametric
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin